Small Pharma Announces TSXV Approval of Normal Course Issuer Bid Post published:August 18, 2022 Post category:Press Release
FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE Post published:August 18, 2022 Post category:Press Release
Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022 Post published:August 17, 2022 Post category:Press Release
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health Post published:August 16, 2022 Post category:Press Release
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update Post published:August 16, 2022 Post category:Press Release
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Post published:August 16, 2022 Post category:Press Release
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study Post published:August 15, 2022 Post category:Press Release
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital Post published:August 15, 2022 Post category:Press Release
Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing Post published:August 13, 2022 Post category:Press Release
PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application Post published:August 12, 2022 Post category:Press Release